Tag: Heraeus Medical
– Agreement includes Right of First Refusal for an orthopaedic indication
Heraeus Holding (Heraeus), a Fortune 500 technology group, has announced the completion of an equity investment in Ankasa Regenerative Therapeutics Inc. (Ankasa), a California-based regenerative medicine company.
Ankasa is focused on pharmaceutical preparations for reactivation of stem cells for organ and tissue regrowth, tissue repair and healing. The company is focusing on the development of the stem cell growth factor WNT3A, which is found in humans and functions in the maintenance of bone growth and repair, but the level of which declines with age. Ankasa intends to develop a proprietary localized therapy involving WNT3A for spinal fusion surgery patients as well as the use in additional bone and other tissue repair applications.
Ankasa´s solution is strategically relevant for Heraeus Medical GmbH, a subsidiary of Heraeus Holding. Heraeus Medical, awarded as a TOP 100 innovative company in Germany, develops biomaterials and medical devices for orthopedic surgery, traumatology and biosurgery.
Following recent early-stage investments, Heraeus continues to actively seek enabling technologies and development partners in the burgeoning field of regenerative medicine in order to accelerate its product development pipeline.
Financial terms of the investment by Heraeus were not disclosed.